The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / November / Adaptive Sampling Advances Pediatric Cancer Profiling
Oncology Omics Precision medicine Research and Innovations Molecular Pathology

Adaptive Sampling Advances Pediatric Cancer Profiling

Rapid nanopore sequencing identifies cancer mutations within hours, offering a potential alternative to multiple diagnostic tests

11/16/2026 News 2 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Scorecard
  • Quiz
  • Poll

Share

Credit: Adobe Stock (Edited)

A single whole-genome sequencing assay can identify the major genetic alterations driving childhood cancers, with many clinically important findings available within 24 hours, according to research published in Genome Medicine. The approach could accelerate molecular diagnosis and help clinicians make earlier decisions about cancer classification, risk assessment, and treatment.

Researchers in Canada evaluated whole-genome sequencing with adaptive sampling (AS-WGS), a technique that concentrates sequencing on selected cancer-associated genes while retaining information from across the genome. Unique to nanopore sequencing, it allows researchers to select, in real time, which DNA molecules to sequence, enriching regions of interest or depleting unwanted material without extra sample preparation.

Using nanopore sequencing, the team analyzed 36 samples from 35 pediatric patients, including 31 tumor samples representing leukemias and solid cancers. The assay targeted approximately 380 clinically relevant genomic regions. Researchers also developed an open-source analysis pipeline, nf-core-oncoseq, to support interpretation while sequencing was underway.

Compared with conventional diagnostic testing, AS-WGS detected all 20 previously identified gene fusions, mutations in 58 of 59 affected genes, and 20 of 21 large copy-number alterations. Importantly, the assay detected mutations present in as little as 5 percent of the sequenced DNA, approaching the sensitivity of clinical exome sequencing.

The greatest advantage was speed. All 20 gene fusions and all 47 evaluated mutations with variant allele frequencies above 25 percent had at least five supporting sequencing reads within 24 hours. Large chromosomal alterations could be identified within the first hour.

Lead researcher Vincent-Phillippe Lavallée, from the Centre de recherche Azrieli du CHU Sainte-Justine, said, "Real-time sequencing and analysis can deliver the first clinically relevant insights within hours, with comprehensive molecular profiles available within days. From a clinical perspective, this could enable precision diagnostics early in the patient’s care journey, supporting timely risk stratification and tailored treatment decisions. Ultimately, this approach could also transform how future clinical trials are designed, by enabling earlier molecular risk stratification and more informed patient selection."

The approach also preserved DNA methylation information, enabling an additional layer of tumor classification without separate testing. Methylation-based analysis correctly classified nine of 11 acute lymphoblastic leukemia samples and eight of 12 solid tumors.

For diagnostic laboratories, combining mutation detection, chromosomal analysis, and methylation profiling in one workflow could reduce reliance on multiple assays, potentially conserving tumor material and shortening turnaround times.

"Adaptive sampling has the potential to transform cancer diagnostics by bringing multiple testing strategies into a single, comprehensive assay," said Lavallée. "In our study, we demonstrated that a single experiment could detect the major classes of clinically relevant genomic alterations in pediatric oncology while also supporting DNA methylation-based tumor classification. This is particularly valuable in heterogeneous and complex diseases, such as pediatric cancers, where comprehensive molecular characterization is essential but normally requires multiple complementary assays and precious tumor material."

The AS-WGS approach may also have a cost advantage. The researchers estimated sequencing costs at approximately CAD $1,700 per sample, compared with more than CAD $5,000 for the combined conventional approaches.

However, some variants required manual review, and detecting low-frequency mutations could still require 72 hours of sequencing. DNA quality and sequencing performance also affected results. Further clinical validation will be needed to establish whether the approach can replace existing diagnostic workflows and improve treatment decisions.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.